Mr. Frandé has been in the pharmaceutical industry for thirty-seven (37) years, thirty-four (34) of those in Oncology with Bristol-Myers, Schering Plough, Immunex, Sanofi-Aventis and for the past 6 years with Astellas. He has served in a variety of capacities during this time, of which, the past 20 years has been dedicated to Account Management. The most notable product launches he’s been part of and supported in one way or another are Intron® A (interferon alfa-2b, recombinant; 1986), Leukine® (Sargramostim (yeast expressed GM-CSF)); 1991), Eloxatin® (Oxaliplatin; 2002) and XTANDI® (enzalutamide; 2012).
Mr. Frande received his B.S. in Biology from Mount St Mary’s College and RRT from University of Chicago.